Compare · AXSM vs TNYA
AXSM vs TNYA
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Tenaya Therapeutics Inc. (TNYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AXSM focuses on Biotechnology: Pharmaceutical Preparations, while TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- AXSM is the larger of the two at $11.84B, about 66.8x TNYA ($177.3M).
- Over the past year, AXSM is up 106.0% and TNYA is down 7.9% - AXSM leads by 113.9 points.
- AXSM has been more active in the news (7 items in the past 4 weeks vs 6 for TNYA).
- AXSM has more recent analyst coverage (25 ratings vs 7 for TNYA).
- Company
- Axsome Therapeutics Inc.
- Tenaya Therapeutics Inc.
- Price
- $229.98-2.90%
- $0.81-3.66%
- Market cap
- $11.84B
- $177.3M
- 1M return
- -8.72%
- +15.75%
- 1Y return
- +106.00%
- -7.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 7
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest AXSM
- Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
- Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
- Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
- Chief Executive Officer Tabuteau Herriot exercised 49,666 shares at a strike of $4.95 and sold $11,932,256 worth of shares (49,666 units at $240.25) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
- Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
- Director Jeffs Roger sold $141,656 worth of shares (572 units at $247.65) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 58,367 units (SEC Form 4)
Latest TNYA
- SEC Form 3 filed by new insider Hyllengren Eric J
- SEC Form 4 filed by Chief Financial Officer Hyllengren Eric J
- Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Tenaya Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Tenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
- Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
- Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
- SEC Form 4 filed by Director Williams R Sanders
- SEC Form 4 filed by Director Walsh Jeffrey T.